<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168331">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117999</url>
  </required_header>
  <id_info>
    <org_study_id>SEA_27</org_study_id>
    <secondary_id>PON01_00110</secondary_id>
    <nct_id>NCT02117999</nct_id>
  </id_info>
  <brief_title>Transepithelial Corneal Cross-linking Using Iontophoresis</brief_title>
  <acronym>TCXLionto</acronym>
  <official_title>Randomized Clinical Trial Comparing Transepithelial Corneal Cross-linking Using Iontophoresis and Standard Corneal Cross-linking for the Treatment of Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council (CNR, Italy)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione G.B. Bietti, IRCCS</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present Randomized Clinical Trial (RCT) is to compare the efficacy and
      safety of transepithelial corneal cross-linking (CXL) using iontophoresis to treat
      progressive keratoconus in comparison with standard CXL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Keratoconus is a progressive corneal ecstatic disease causing visual impairment by inducing
      irregular astigmatism and corneal opacities. This disorder typically begins during the
      second decade of life and, in severe forms, may need a corneal transplantation. Corneal
      cross-linking (CXL) is a procedure intended to halt keratoconus progression. It creates
      links between stromal proteins in order to stiffen the corneal tissue. Standard CXL includes
      epithelial removal and stroma soaking with dextran-enriched 0.1% riboflavin solution for 30
      minutes before being exposed to ultraviolet-A radiation using a  3mW/cm2 lamp for 30
      minutes.

      Epithelial debridement expose the cornea to a risk of side effects, such as pain for the
      first two post-operative days, temporary loss of visual acuity during the first three
      months, and serious complications such as infection and stromal opacity due to corneal
      scarring.

      Iontophoresis is a non invasive technique in which a weak electric current is used to
      enhance the penetration of hypotonic 0.1% riboflavin-5-phosphate solution into the corneal
      stroma through the intact epithelium. After iontophoresis, the corneal tissue is irradiated
      using a 10 mW/cm2 for 9 minutes (TCXLionto). From previous experimental work (Lombardo M. et
      al. J Cataract Refract Surg 2014), the investigators provided evidence that TCXLionto
      increases the stiffness of human corneas with results almost comparable with standard CXL.
      The new procedure thus holds the promise to be as effective as the standard procedure while
      minimizing all the related risks. It is object of the present clinical trial to randomize
      patients with progressive keratoconus to TCXLionto and standard CXL and compare efficacy and
      safety of treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>K-max</measure>
    <time_frame>Changes from baseline in Kmax at 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring maximum keratometry (K-max) derived from computerized videokeratography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal endothelial cell density</measure>
    <time_frame>Changes from baseline in ECD at 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Endothelial cell density (ECD) will be evaluated using specular microscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simulated keratometry</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measures assessed by corneal tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical aberrations</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Optical aberrations of the eye will be measured using dynamic skyascopy. Corneal wavefront aberration will be measured using Placido disk topographer and Scheimpflug tomographer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual acuity tested using ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Contrast sensitivity tested using Pelli-Robson chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PAin score will graded by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Central retinal thickness (1 mm ETDRS map) will be measured before and after CXL procedures</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Corneal biomechanical behaviour</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>No-contact tonometry readings and strain response of the cornea to air-puff evaluated using ORA</description>
  </other_outcome>
  <other_outcome>
    <measure>Demarcation line</measure>
    <time_frame>Changes from baseline at 12 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>OCT scans of the cornea will be acquired using Visante device</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Progressive Keratoconus</condition>
  <arm_group>
    <arm_group_label>Transepithelial corneal cross-linking using iontophoresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapid transepithelial corneal cross-linking using iontophoresis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard corneal cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard corneal cross-linking</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transepithelial corneal cross-linking using iontophoresis</intervention_name>
    <description>The procedure involves a constant current source and two electrodes. The main electrode is a bath tube, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA  10mW/cm2 for 9 minutes.</description>
    <arm_group_label>Transepithelial corneal cross-linking using iontophoresis</arm_group_label>
    <other_name>Ricrolin+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard corneal cross-linking</intervention_name>
    <description>In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp 3mW/cm2 for 30 minutes.</description>
    <arm_group_label>Standard corneal cross-linking</arm_group_label>
    <other_name>Ricrolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of progressive keratoconus

        Exclusion Criteria:

          -  Anterior corneal curvature steeper than 61 D;

          -  central corneal thickness &lt;400 um

          -  corneal scarring;

          -  descemetocele;

          -  history of herpetic keratitis;

          -  Concomitant eye diseases;

          -  Inflammatory eye diseases;

          -  Glaucoma;

          -  Cataract;

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Lombardo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione G.B. Bietti, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Lombardo, MD, PhD</last_name>
    <phone>+393388136737</phone>
    <email>mlombardo@visioeng.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione G.B. Bietti, IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Lombardo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fondazionebietti.it</url>
    <description>Inclusion and exclusion criteria to the present RCT are shown in the main website page</description>
  </link>
  <reference>
    <citation>Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998 Jan;66(1):97-103.</citation>
    <PMID>9533835</PMID>
  </reference>
  <reference>
    <citation>Hao J, Li SK, Liu CY, Kao WW. Electrically assisted delivery of macromolecules into the corneal epithelium. Exp Eye Res. 2009 Dec;89(6):934-41. doi: 10.1016/j.exer.2009.08.001. Epub 2009 Aug 12.</citation>
    <PMID>19682448</PMID>
  </reference>
  <reference>
    <citation>Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006 Feb 21;110(3):479-89. Epub 2005 Dec 15. Review.</citation>
    <PMID>16343678</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione G.B. Bietti, IRCCS</investigator_affiliation>
    <investigator_full_name>Marco Lombardo</investigator_full_name>
    <investigator_title>Dr. Marco Lombardo</investigator_title>
  </responsible_party>
  <keyword>corneal cross-linking</keyword>
  <keyword>transepithelial corneal cross-linking</keyword>
  <keyword>iontophoresis</keyword>
  <keyword>progressive keratoconus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
